ONCAlert | 2017 San Antonio Breast Cancer Symposium

Ongoing Trials Studying Immunotherapy as a First-Line Treatment in Head and Neck Cancer

Barbara Ann Burtness, MD
Published Online:12:50 PM, Mon October 3, 2016

Barbara Ann Burtness, MD, professor of medicine, Clinical Research Program Leader, Head and Neck Cancers Program and Co-Director, Developmental Therapeutics Research Program at Yale Cancer Center, discusses the ongoing trials looking at immunotherapy as a first-line treatment in head and neck cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.